04/08/22 -"We have adjusted our EPS estimates for the additional costs associated with the acquistion of AKKA and a lower than anticipated net income realisation in H1. These estimates have also been impacted ..."
Pages
51
Language
English
Published on
04/08/22
You may also be interested by these reports :
21/10/25
Eurofins Scientific’s Q3 results were broadly in line with our expectations and Visible Alpha consensus. The organic growth was slightly below ...
07/10/25
FICO’s launch of the Mortgage Direct Licence Programme – which allows resellers to obtain scores directly from them, thereby bypassing credit ...
23/09/25
After a decent close to 2024 (i.e. March-end FY25), management guidance for 2025 seemed overambitious, given the macro environment, especially ...
04/09/25
The change in the target price reflects the update of our estimates and the effect on DCF and peer-based valuations. Despite a challenging macro ...